Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 7/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.51 |
| ▸ | LMNA | P02545 | 3/20 | 0.50 |
| ▸ | GAA | P10253 | 2/20 | 0.48 |
| ▸ | SLC6A7 | Q99884 | 1/20 | 0.48 |
| ▸ | GRM5 | P41594 | 2/20 | 0.48 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | FLT3 | P36888 | 2/20 | 0.46 |
| ▸ | KIT | P10721 | 1/20 | 0.46 |
| ▸ | ME2 | P23368 | 1/20 | 0.45 |
| ▸ | ME1 | P48163 | 1/20 | 0.45 |
| ▸ | ME3 | Q16798 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2311957 | 1.00 | MAPT (0.55) | MAPTKDM4EKMT2ALMNAGAA | |
| SCHEMBL2311306 | 0.89 | MAPT (0.55) | MAPTKDM4EKMT2ALMNAGAA | |
| SCHEMBL12206662 | 0.89 | MAPT (0.61) | MAPTKDM4EKMT2ALMNAGAA | |
| SCHEMBL2309957 | 0.86 | MAPT (0.52) | MAPTKDM4EKMT2ALMNAGAA | |
| SCHEMBL12206763 | 0.86 | MAPT (0.52) | MAPTKDM4EKMT2ALMNAGAA | |
| SCHEMBL12206659 | 0.86 | MAPT (0.51) | MAPTKDM4EKMT2ALMNAGAA | |
| SCHEMBL12231798 | 0.86 | MAPT (0.60) | MAPTKDM4EKMT2ALMNAGAA | |
| SCHEMBL12206657 | 0.83 | MAPT (0.56) | MAPTKDM4EKMT2ALMNAGAA | |
| SCHEMBL12231799 | 0.82 | MAPT (0.55) | MAPTKDM4EKMT2ALMNAGAA | |
| SCHEMBL988322 | 0.82 | MAPT (0.57) | MAPTKDM4EKMT2ALMNAGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110250135-A1 | Piperazine Derivatives for Binding and Imaging Amyloid Plaques and Their Use | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-10-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110250135-A1 | Piperazine Derivatives for Binding and Imaging Amyloid Plaques and Their Use | APP, APBA1, PSEN1 | MAPT 14/4885KDM4E 4658/4885KMT2A 4443/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.